Wanti
Wanting on the underlying holdings of the ETFs in our protection universe at ETF Channel, we’ve got in contrast the buying and selling value of every holding towards the typical analyst 12-month ahead goal value, and computed the weighted common implied analyst goal value for the ETF itself. For the Biotech ETF (Image: BBH), we discovered that the implied analyst goal value for the ETF primarily based upon its underlying holdings is $157.83 per unit.
With BBH buying and selling at a latest value close to $138.77 per unit, that signifies that analysts see 13.73% upside for this ETF wanting by means of to the typical analyst targets of the underlying holdings. Three of BBH’s underlying holdings with notable upside to their analyst goal costs are Sarepta Therapeutics Inc (Image: SRPT), bluebird bio Inc (Image: BLUE), and EXACT Sciences Corp. (Image: EXAS). Though SRPT has traded at a latest value of $124.63/share, the typical analyst goal is 58.82% greater at $197.93/share. Equally, BLUE has 52.14% upside from the latest share value of $86.63 if the typical analyst goal value of $131.80/share is reached, and analysts on common expect EXAS to succeed in a goal value of…